

Special Issue

Crosstalk between Metabolic Syndrome and Voiding Dysfunction

Message from the Guest Editors

Metabolic syndrome and its associated diseases—hypertension, diabetes, and dyslipidemia, among others—have been a matter of public health for decades. Similarly, voiding dysfunction and lower urinary tract symptoms (LUTS) increase in prevalence with aging and affect a significant share of the population. Clinical studies have clearly established a link between both conditions, but so far, shared biological and cellular mechanisms are lacking. Nevertheless, significant progress has been made thanks to several cutting-edge techniques relying on metabolomics, proteomics, new biomarker identification in body fluids, as well as gene knockout mice, laser microdissection, and analyses of gene expression. This Special Issue of *Metabolites*, "Crosstalk between Metabolic Syndrome and Voiding Dysfunction", will be dedicated to the most recent discoveries unraveling the relationship between bladder dysfunction and systemic metabolic parameters. These encompass gene expression, urinary and plasma metabolites, hormones and biomarkers, and non-invasive discovery of new clinical biomarkers.

Guest Editors

Dr. Lysanne Campeau


Division of Urology, Department of Surgery, Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal, QC H3T 1E2, Canada

Dr. Philippe G. Cammisotto

Lady Davis Institute for Medical Research, Montreal, Canada

Deadline for manuscript submissions

closed (31 May 2023)



Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



mdpi.com/si/110252

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).